Contributions
Abstract: PB1800
Type: Publication Only
Session title: Stem cell transplantation - Experimental
Background
Autotransplantation of hematopoietic stem cells (HSC) (AutoHSCT) is the standard of therapy for young and middle-aged patients with multiple myeloma (MM) and is performed in order to restore hematopoiesis. Mandatory step AutoHSCT is the cryopreservation of HSC on the time required for high-dose chemotherapy or to re-AutoHSCT. The quality of the autograft depends on the speed of solving postsimulation aplasia of the bone marrow. Markers of autograft quality are the number of CD34+cells and the proliferative potential of HSCs, which can be judged by their colony-forming ability (CFA). When evaluating CFA, three indicators are taken into account separately: the number of granulocyte-macrophage colony-forming units (CFU-GM), erythroid burst-forming units (BFU-E), and total colony-forming units (CFU-total).
Aims
To evaluate the viability and proliferative potential of HSCs prepared for AutoHSCT in MM patients by the number of CD34+cells and CFA HSCs, depending on the timing of their cryopreservation.
Methods
CFA HSCs were evaluated based on the results of 12-14 days of cell culture in MethoCult H4435. CD34+cells were determined on a Cytomics FC500 flow laser cytofluorometer using a set of Stem Kit Reagents.
A retrospective analysis of autograft parameters during harvesting and subsequent transplantation, depending on the timing of cell cryopreservation, was performed in MM patients aged 32 to 68 years. The duration of cryopreservation ranged from 2 weeks to 1.5 years, with a median of 6 months. Depending on the shelf life, patients were divided into 3 groups: group 1 - shelf life from 1 to 5.9 months (n=83); group 2 - from 6 to 10 months (n=34); and group 3 - ≥ 10 months (n=10). The data of 91 MM patients were analyzed, the total number of analyzed cases was 127.
Results
The number of total CFU in group 1 is reduced to 66% of the original, in the second group to 60%, in group 3 to 44%. In groups 1 and 2, there was a proportional decrease in both CFU-GM and BFU-E. However, in group 3, with cryopreservation periods of more than 10 months, a statistically significant decrease in the number of BFU-E was shown; p=0.01. In the same group, patients with longer platelet recovery periods were noted.
The number of CD34+cells after cryopreservation is reduced to 77 % in group 1, 39% in group 2 and 49% in group 3. No statistically significant correlations with the shelf life were found, probably due to the wide range of values in all groups, but a significant decrease in the number of CD34+cells was shown. Even in group 1 with a minimum shelf life, the number of cells decreased by almost a third. The CFA results obtained are comparable to the reduced number of CD34+cells in the samples.
Conclusion
The data obtained by us indicate a reduction in the number of CD34+cells and a decrease in their proliferative potential according to the CFA data already in the group with a minimum shelf life. The lowest values were found in the group with a shelf life of more than 10 months. The results of the study show the expediency of earlier preparation of the autograft, eliminating the possibility of a negative impact of previous induction therapy, in order to obtain a cell suspension with the maximum content of HSC, especially when planning tandem or repeated AutoHSCT in patients with newly diagnosed MM.
Keyword(s): Autologous hematopoietic stem cell transplantation, Cryopreservation, Hematopoietic stem cell, Multiple myeloma
Abstract: PB1800
Type: Publication Only
Session title: Stem cell transplantation - Experimental
Background
Autotransplantation of hematopoietic stem cells (HSC) (AutoHSCT) is the standard of therapy for young and middle-aged patients with multiple myeloma (MM) and is performed in order to restore hematopoiesis. Mandatory step AutoHSCT is the cryopreservation of HSC on the time required for high-dose chemotherapy or to re-AutoHSCT. The quality of the autograft depends on the speed of solving postsimulation aplasia of the bone marrow. Markers of autograft quality are the number of CD34+cells and the proliferative potential of HSCs, which can be judged by their colony-forming ability (CFA). When evaluating CFA, three indicators are taken into account separately: the number of granulocyte-macrophage colony-forming units (CFU-GM), erythroid burst-forming units (BFU-E), and total colony-forming units (CFU-total).
Aims
To evaluate the viability and proliferative potential of HSCs prepared for AutoHSCT in MM patients by the number of CD34+cells and CFA HSCs, depending on the timing of their cryopreservation.
Methods
CFA HSCs were evaluated based on the results of 12-14 days of cell culture in MethoCult H4435. CD34+cells were determined on a Cytomics FC500 flow laser cytofluorometer using a set of Stem Kit Reagents.
A retrospective analysis of autograft parameters during harvesting and subsequent transplantation, depending on the timing of cell cryopreservation, was performed in MM patients aged 32 to 68 years. The duration of cryopreservation ranged from 2 weeks to 1.5 years, with a median of 6 months. Depending on the shelf life, patients were divided into 3 groups: group 1 - shelf life from 1 to 5.9 months (n=83); group 2 - from 6 to 10 months (n=34); and group 3 - ≥ 10 months (n=10). The data of 91 MM patients were analyzed, the total number of analyzed cases was 127.
Results
The number of total CFU in group 1 is reduced to 66% of the original, in the second group to 60%, in group 3 to 44%. In groups 1 and 2, there was a proportional decrease in both CFU-GM and BFU-E. However, in group 3, with cryopreservation periods of more than 10 months, a statistically significant decrease in the number of BFU-E was shown; p=0.01. In the same group, patients with longer platelet recovery periods were noted.
The number of CD34+cells after cryopreservation is reduced to 77 % in group 1, 39% in group 2 and 49% in group 3. No statistically significant correlations with the shelf life were found, probably due to the wide range of values in all groups, but a significant decrease in the number of CD34+cells was shown. Even in group 1 with a minimum shelf life, the number of cells decreased by almost a third. The CFA results obtained are comparable to the reduced number of CD34+cells in the samples.
Conclusion
The data obtained by us indicate a reduction in the number of CD34+cells and a decrease in their proliferative potential according to the CFA data already in the group with a minimum shelf life. The lowest values were found in the group with a shelf life of more than 10 months. The results of the study show the expediency of earlier preparation of the autograft, eliminating the possibility of a negative impact of previous induction therapy, in order to obtain a cell suspension with the maximum content of HSC, especially when planning tandem or repeated AutoHSCT in patients with newly diagnosed MM.
Keyword(s): Autologous hematopoietic stem cell transplantation, Cryopreservation, Hematopoietic stem cell, Multiple myeloma